Anti-oestrogenic chemoprevention of breast cancer—the need to progress
- 31 March 2003
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (5) , 572-579
- https://doi.org/10.1016/s0959-8049(02)00771-2
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Tamoxifen for breast cancer among hysterectomised womenThe Lancet, 2002
- Estrogen and the Risk of Breast CancerNew England Journal of Medicine, 2001
- Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast CancerJNCI Journal of the National Cancer Institute, 1999
- Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast CancerAnnals of Internal Medicine, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancerBritish Journal of Cancer, 1989
- Hormonal Pathogenesis of Adenocarcinoma of the BreastThe American Journal of Cancer, 1936